Navigation Links
Westaim terminates reorganization agreement and cancels shareholders' meeting
Date:11/4/2008

CALGARY, Nov. 4 /PRNewswire-FirstCall/ - The Westaim Corporation announced today that its reorganization agreement with several western Canadian construction services companies has been terminated.

Under the terms of the proposed reorganization agreement dated on October 3, 2008, subscription agreements for a private placement of common shares for gross proceeds of $15 million were required to be signed and delivered within 14 days of the mailing of the information circular for Westaim's special meeting of shareholders. Due to the current volatile state of the financial markets and the general state of the investment climate, sufficient subscribers for the private placement could not be found.

As a consequence of terminating the reorganization agreement, Westaim has cancelled the shareholders' meeting called for November 21, 2008.

"Westaim will continue its review of strategic alternatives in light of this development," said Drew Fitch, President & CEO, The Westaim Corporation. "The board of directors will examine all possible options for the longer-term structure of the company moving forward and remain committed to realizing maximum value for shareholders."

The Westaim Corporation's common shares are listed on The Toronto Stock Exchange under the trading symbol WED.


'/>"/>
SOURCE Westaim Corporation
Copyright©2008 PR Newswire.
All rights reserved

Page: 1

Related medicine news :

1. Westaim to deregister its common stock in the United States
2. Westaim announces sale of iFire Technology Ltd. assets
3. Westaim announces 2008 second quarter results
4. Webcast Advisory - The Westaim Corporation Webcast of Conference Call to Discuss 2008 Second Quarter Results
5. Westaim announces 2008 first quarter results
6. Webcast Advisory - The Westaim Corporation Webcast of Annual Meeting of Shareholders
7. Westaim announces 2007 year-end results
8. Webcast Advisory - The Westaim Corporation Webcast of Conference Call to Discuss 2007 Fourth Quarter Results
9. Westaim reduces ABCP exposure
10. Westaim announces 2007 third quarter results
11. Webcast Advisory - The Westaim Corporation Webcast of Conference Call to Discuss 2007 Third Quarter Results
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/30/2017)... ... March 30, 2017 , ... ... educational offerings of corporate finance programs to address the increasingly complex educational needs ... executives increase their knowledge of sophisticated corporate finance and will increase their ability ...
(Date:3/30/2017)... , ... March 30, 2017 , ... ... submitted a letter to President Trump expressing their support for an independent Vaccine ... two Ph.D. scientists and one medical journalist, will hold a press conference at ...
(Date:3/29/2017)... (PRWEB) , ... March 29, 2017 , ... Full Contact ... founder of Pet Protect Law that assists dog owners in creating legally-enforceable ... new owners in taking the natural next step to protect their new companion. Says ...
(Date:3/29/2017)... ... March 30, 2017 , ... Sports Brand EXOUS Bodygear announced today ... normally at $29.97; for the remaining days of March, the price will be only ... a special price of just $10 (regular retail price $19.97). , The special promotional ...
(Date:3/29/2017)... ... March 29, 2017 , ... Patients interested ... Carnegie, OK, from Dr. Jamie Cameron, with or without a referral. The FASTBRACES ... orthodontic treatment. Depending on each patient’s case, treatment with the FASTBRACES system could ...
Breaking Medicine News(10 mins):
(Date:3/29/2017)... 2017  Experts in the field in alcohol ... Soberlink Systems  as a model for recovery through ... early 2017, concluded that remote blood alcohol monitoring ... recovery." The findings of the expert ... detail a range of variables that are commonplace ...
(Date:3/29/2017)... March 29, 2017  Glenmark Pharmaceuticals, a global ... 301, an investigational fixed-dose combination of mometasone furoate ... twice-daily as a nasal spray being studied for ... are from a recently completed Phase 3 trial ... combination therapy versus mometasone, olopatadine or placebo. ...
(Date:3/29/2017)... 29, 2017 Research and Markets has announced ... report to their offering. ... The global lifestyle drugs market to grow at a ... report, Global Lifestyle Drugs Market 2017-2021, has been prepared based on ... covers the market landscape and its growth prospects over the coming ...
Breaking Medicine Technology: